Q-omics provides the consensus-scored CD2BP2-DT profile across patient tissues and cancer cell-line models. CD2BP2-DT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CD2BP2-DT is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CD2BP2-DT RNA expression shows 13,138 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where CD2BP2-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD2BP2-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD2BP2-DT survival associations across molecular data types. CD2BP2-DT RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD2BP2-DT RNA expression–survival associations across cancer types. High CD2BP2-DT expression shows unfavorable associations in UVM, LGG and ACC, but favorable associations in MESO, LUAD and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CD2BP2-DT RNA expression.
This table summarizes CD2BP2-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CD2BP2-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD2BP2-DT shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, LIHC, HNSC and BRCA. The KIRC box plot shows higher CD2BP2-DT RNA expression in tumor versus normal tissue (log2 FC = +1.056, t-test p < 0.001).
This table shows molecular features associated with CD2BP2-DT in patient tissues and cancer cell lines. In patient samples, CD2BP2-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
